Valve in Valve Trans-Catheter Aortic Valve Replacement Followed by LVAD Deactivation in the Setting of Recovered Systolic Function

Author(s): Abdel R. Al Emam*, David Barton, John Um, Gregory Pavlides.

Journal Name: Current Cardiology Reviews

Volume 16 , Issue 1 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Advanced heart failure has extremely high mortality without advanced therapies (left ventricular assist device (LVAD) implantation or cardiac transplant). LVAD patients with bioprosthetic aortic valve are more prone to leaflet fusion resulting in valvular stenosis and regurgitation.

Case Presentation: We present a 46-year-old patient who had LV systolic function recovery while on LVAD. However, he had a severely stenotic aortic valve bioprosthesis with leaflet fusion that had to be replaced before deactivating his LVAD. Due to high surgical risk, we performed valve-invalve Trans-Catheter Aortic Valve Replacement (TAVR) with an Evolut self-expanding valve, however, the patient had significant aortic regurgitation secondary to deployment above the bioprosthetic valve ring. We successfully deployed a second Evolut Self-expanding valve inside the ring with excellent results. This was followed by a successful LVAD deactivation next day. His LV systolic function continued to recover and he had no heart failure symptoms at 3 month follow up. In the right settings, TAVR in recovered LVAD patients with aortic stenosis as a bridge to LVAD deactivation is a viable option, especially for patients who fall in the high-risk group.

Conclusion: To the best of our knowledge, this is the first reported case of a valve-in-valve TAVR followed by successful LVAD deactivation in the setting of recovered LV systolic function.

Keywords: Left ventricular assist device, trans-catheter aortic valve replacement, valve in valve, heart failure, cardiac transplant, stenosis, non-ischemic cardiomyopathy.

[1]
Parikh KS, Mehrotra AK, Russo MJ, et al. Percutaneous transcatheter aortic valve closure successfully treats left ventricular assist device-associated aortic insufficiency and improves cardiac hemodynamics. JACC Cardiovasc Interv 2013; 6(1): 84-9.
[http://dx.doi.org/10.1016/j.jcin.2012.08.021] [PMID: 23347865]
[2]
Mozaffarian D, Benjamin EJ, Go AS, et al. AHA Statistical Update Heart Disease and Stroke Statistics. American Heart Association WRITING GROUP MEMBERS 2016.
[3]
Wever-Pinzon O, Drakos SG, McKellar SH, et al. Cardiac Recovery During Long-Term Left Ventricular Assist Device Support. J Am Coll Cardiol 2016; 68(14): 1540-53.
[http://dx.doi.org/10.1016/j.jacc.2016.07.743] [PMID: 27687196]
[4]
Khan S, Koerner MM, Pae W, et al. Successful percutaneous transcatheter aortic valve replacement in multi-organ failure due to aortic bioprosthesis regurgitation in a patient with continuous-flow LVAD. J Heart Lung Transplant 2013; 32(6): 659-63.
[http://dx.doi.org/10.1016/j.healun.2013.03.007] [PMID: 23701856]
[5]
Phan AK. Copyright © 2016 by the American Society for Artificial Internal Organs Copyright © 2016 by the American Society for Artificial Internal Organs. 1-23.2016;
[6]
Webb JG, Dvir D. Transcatheter aortic valve replacement for bioprosthetic aortic valve failure: The valve-in-valve procedure. Circulation 2013; 127(25): 2542-50.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.000631] [PMID: 23797741]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 1
Year: 2020
Page: [77 - 80]
Pages: 4
DOI: 10.2174/1573403X15666190509082833
Price: $65

Article Metrics

PDF: 19
HTML: 2